Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst

David Smart/Shutterstock.com

Summit Therapeutics Inc. (NASDAQ:SMMT) has stated that it would disagreement its HARMONi-3 proceedings into 2 histological cohorts, comparing ivonescimab with chemotherapy to pembrolizumab positive chemotherapy successful the first-line regimen for metastatic squamous and non-squamous NSCLC.

The institution intends to contiguous preliminary findings for the HARMONi-3 squamous colonisation successful the second fractional of 2026, with enrollment successful the non-squamous cohort projected to reason successful the aforesaid period. Summit Therapeutics Inc. (NASDAQ:SMMT) estimates that the non-squamous cohort volition walk the progression-free endurance lawsuit threshold successful the archetypal fractional of 2027.

According to Cantor Fitzgerald, the study’s findings person the imaginable to beryllium “biotech’s astir important catalyst successful 2026” and “the biggest binary lawsuit successful the past of biotech.”

Summit Therapeutics Inc. (NASDAQ:SMMT) is simply a biopharmaceutical institution processing treatments for superior unmet aesculapian needs, chiefly successful oncology, with its pb drug, ivonescimab, a bispecific antibody.

While we admit the imaginable of SMMT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.